Stilianos Giannakopoulos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Stilianos Giannakopoulos has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
Christos Kalaitzis
Department of Urology, Democritus University of Thrace, Alexandroupolis, Greece
14 shared publicationsStavros Touloupidis
Democritus Univ Thrace, Dept Urol, Alexandroupolis, Greece
12 shared publications- Dimitrios Diamantidis
Department of Urology, Democritus University of Thrace, 68100 Alexandroupolis, Greece
9 shared publications - Georgios Tsakaldimis
Department of Urology, Democritus University of Thrace, Alexandroupolis, Greece
6 shared publications Stavros Giannopoulos
Department of Urology, Democritus University of Thrace, Alexandroupolis, Greece
6 shared publicationsAthanasios Bantis
Department of Urology, Democritus University of Thrace, Alexandroupolis, Greece
5 shared publications
Latest Publications
- Open Access
- 26 September 2026
- Published by MDPI AG in Journal of Imaging
- Vol. 12 (10) , 469
Modern Imaging and the Future of Prostate Biopsy: Rethinking Systematic Sampling
Prostate biopsy has shifted from systematic, non-targeted sampling towards imaging-directed approaches, but the extent to which systematic cores can be safely reduced remains uncertain. This review examines current evidence on contemporary biopsy strategies in men with suspected prostate cancer. A structured PubMed/MEDLINE search through July 2026 identified studies evaluating multiparametric magnetic resonance imaging (mpMRI), MRI-targeted biopsy, perilesional, regional and ipsilateral sampling, micro-ultrasound, prostate-specific membrane antigen positron emission tomography (PSMA PET), radiomics, and artificial intelligence. MRI-targeted biopsy improves the detection of clinically significant disease and reduces low-grade cancer diagnosis, yet targeted sampling alone may miss or undergrade clinically important tumours. Available evidence suggests that perilesional, regional, or ipsilateral sampling can preserve much of the diagnostic contribution of systematic biopsy while reducing unnecessary cores, although the evidence remains heterogeneous and is frequently retrospective. Micro-ultrasound and PSMA PET may further refine lesion localisation, while artificial intelligence may support risk assessment and biopsy planning. Current evidence supports selective reduction in systematic sampling, not its universal omission. Future biopsy strategies should integrate clinical risk, imaging quality, lesion characteristics, and targeting confidence and require prospective multicentre validation before broad implementation.
- 26 September 2026
- Published by MDPI AG in Journal of Imaging
- Vol. 12 (10) , 469
Open AccessModern Imaging and the Future of Prostate Biopsy: Rethinking Systematic Sampling
Prostate biopsy has shifted from systematic, non-targeted sampling towards imaging-directed approaches, but the extent to which systematic cores can be safely reduced remains uncertain. This review examines current evidence on contemporary biopsy strategies in men with suspected prostate cancer. A structured PubMed/MEDLINE search through July 2026 identified studies evaluating multiparametric magnetic resonance imaging (mpMRI), MRI-targeted biopsy, perilesional, regional and ipsilateral sampling, micro-ultrasound, prostate-specific membrane antigen positron emission tomography (PSMA PET), radiomics, and artificial intelligence. MRI-targeted biopsy improves the detection of clinically significant disease and reduces low-grade cancer diagnosis, yet targeted sampling alone may miss or undergrade clinically important tumours. Available evidence suggests that perilesional, regional, or ipsilateral sampling can preserve much of the diagnostic contribution of systematic biopsy while reducing unnecessary cores, although the evidence remains heterogeneous and is frequently retrospective. Micro-ultrasound and PSMA PET may further refine lesion localisation, while artificial intelligence may support risk assessment and biopsy planning. Current evidence supports selective reduction in systematic sampling, not its universal omission. Future biopsy strategies should integrate clinical risk, imaging quality, lesion characteristics, and targeting confidence and require prospective multicentre validation before broad implementation.
- Open Access
- 25 August 2026
- Published by Wolters Kluwer Health in Current Urology
- Vol. 20 (6) , 332-348
Explainable artificial intelligence in prostate and bladder cancer: A review of imaging, digital pathology, molecular profiling, and clinical data
Artificial intelligence (AI) models are increasingly applied across the detection, staging, treatment selection, and surveillance of prostate and bladder cancer. Explainable AI links predictions to identifiable features, spatial regions, or architectural constraints, supporting clinical audit and informed use. This narrative review synthesizes evidence across both cancers in imaging, digital pathology, molecular and liquid-biopsy data, and clinical applications and assesses deployment readiness. Two parallel structured searches of PubMed/MEDLINE were performed, one for each cancer, covering records through November 15, 2025. Eligible studies applied machine or deep learning to a clinical or translational task and included an explainability component. Seventy studies across 4 data domains were included. Imaging was the most active domain. SHapley Additive exPlanations and gradient-weighted class activation mapping confirmed biologically plausible signal localization. Interpretability-by-design in bladder endoscopy embedded explainability without post hoc approximation. Attention heatmaps and probability maps in digital pathology linked model focus to histological features relevant to grading and invasion. Molecular models ranged from post hoc attribution to pathway-constrained architectures; a biologically structured deep neural network in prostate cancer demonstrated how architectural constraints can move explanations toward mechanistic inference. Clinical and electronic medical record-based models constituted the largest group, using SHapley Additive exPlanations for prebiopsy triage, treatment selection, recurrence prediction, and active surveillance. Post hoc explanations and interpretable-by-design models carry different evidentiary weight. Prospective evidence that explainable AI affects clinical decisions is lacking. Translation requires independent validation of fidelity, stability, and usability, prospective reader studies, standardized reporting, and investment in interpretable architectures.
- 25 August 2026
- Published by Wolters Kluwer Health in Current Urology
- Vol. 20 (6) , 332-348
Open AccessExplainable artificial intelligence in prostate and bladder cancer: A review of imaging, digital pathology, molecular profiling, and clinical data
Artificial intelligence (AI) models are increasingly applied across the detection, staging, treatment selection, and surveillance of prostate and bladder cancer. Explainable AI links predictions to identifiable features, spatial regions, or architectural constraints, supporting clinical audit and informed use. This narrative review synthesizes evidence across both cancers in imaging, digital pathology, molecular and liquid-biopsy data, and clinical applications and assesses deployment readiness. Two parallel structured searches of PubMed/MEDLINE were performed, one for each cancer, covering records through November 15, 2025. Eligible studies applied machine or deep learning to a clinical or translational task and included an explainability component. Seventy studies across 4 data domains were included. Imaging was the most active domain. SHapley Additive exPlanations and gradient-weighted class activation mapping confirmed biologically plausible signal localization. Interpretability-by-design in bladder endoscopy embedded explainability without post hoc approximation. Attention heatmaps and probability maps in digital pathology linked model focus to histological features relevant to grading and invasion. Molecular models ranged from post hoc attribution to pathway-constrained architectures; a biologically structured deep neural network in prostate cancer demonstrated how architectural constraints can move explanations toward mechanistic inference. Clinical and electronic medical record-based models constituted the largest group, using SHapley Additive exPlanations for prebiopsy triage, treatment selection, recurrence prediction, and active surveillance. Post hoc explanations and interpretable-by-design models carry different evidentiary weight. Prospective evidence that explainable AI affects clinical decisions is lacking. Translation requires independent validation of fidelity, stability, and usability, prospective reader studies, standardized reporting, and investment in interpretable architectures.
- Open Access
- 12 August 2026
- Published by Elsevier in Asian Journal of Urology
Clinical integration of tertiary lymphoid structures and B cells in non-muscle-invasive and muscle-invasive bladder cancer
- 12 August 2026
- Published by Elsevier in Asian Journal of Urology
Open AccessClinical integration of tertiary lymphoid structures and B cells in non-muscle-invasive and muscle-invasive bladder cancer
- Open Access
- 19 June 2026
- Published by Elsevier in Asian Journal of Urology
Explainable artificial intelligence in urolithiasis: Applications and future directions
- 19 June 2026
- Published by Elsevier in Asian Journal of Urology
Open AccessExplainable artificial intelligence in urolithiasis: Applications and future directions
- 21 May 2026
- Published by SAGE Publications in Journal of Endourology
- Vol. 40 (8) , 873-878
Are Two Channels Better than One? A Comparative Study Between Dual-Lumen and Single-Lumen Flexible Ureteroscope in Retrograde Intrarenal Surgery
Objective: To compare perioperative efficiency, stone-free rates, and safety between a dual-lumen and a single-lumen flexible ureteroscope in retrograde intrarenal surgery (RIRS). Materials and Methods: This comparative study included 80 consecutive patients with a single renal stone 1.0–1.5 cm in the pelvicalyceal system treated with RIRS using either a dual-lumen ureteroscope (Group A, n = 40) or a single-lumen ureteroscope (Group B, n = 40). Recorded outcomes included operative and fluoroscopy times, failure of ureteral access sheath (UAS) insertion, surgeon-rated clarity of vision (0–10 scale), stone-free status on non-contrast computed tomography at 30 days, and complications graded by the Clavien–Dindo system and the Post-Ureteroscopy Lesion Scale (PULS). The stone-free rate (SFR) was defined as absolute and relative. Results: Baseline demographics, stone size, and stone location were comparable between groups. Dual-lumen use was associated with shorter operative time (38.6 ± 9.3 vs 52.7 ± 8.1 minutes, p = 0.018), shorter fluoroscopy time (23.6 ± 5.5 vs 34.2 ± 4.7 seconds, p = 0.04), and higher clarity-of-vision scores (8.6 ± 1.35 vs 5.9 ± 1.86, p = 0.035). UAS insertion failed more often with the dual-lumen scope (20.0% vs 10.0%, p = 0.32). One month after evaluation, SFR did not significantly differ between the two groups. Postoperative complications were infrequent (12.5% vs 10.0%, p = 0.72), all were Clavien–Dindo grade I–II, and no PULS grade ≥4 ureteral injuries occurred. Conclusions: Compared with a reusable single-lumen ureteroscope, the dual-lumen device improved operative efficiency in terms of shorter operative and fluoroscopy time and better clarity of vision. These benefits are counterbalanced by a higher UAS insertion failure rate related to the larger outer diameter of the ureteroscope.
- 21 May 2026
- Published by SAGE Publications in Journal of Endourology
- Vol. 40 (8) , 873-878
Are Two Channels Better than One? A Comparative Study Between Dual-Lumen and Single-Lumen Flexible Ureteroscope in Retrograde Intrarenal Surgery
Objective: To compare perioperative efficiency, stone-free rates, and safety between a dual-lumen and a single-lumen flexible ureteroscope in retrograde intrarenal surgery (RIRS). Materials and Methods: This comparative study included 80 consecutive patients with a single renal stone 1.0–1.5 cm in the pelvicalyceal system treated with RIRS using either a dual-lumen ureteroscope (Group A, n = 40) or a single-lumen ureteroscope (Group B, n = 40). Recorded outcomes included operative and fluoroscopy times, failure of ureteral access sheath (UAS) insertion, surgeon-rated clarity of vision (0–10 scale), stone-free status on non-contrast computed tomography at 30 days, and complications graded by the Clavien–Dindo system and the Post-Ureteroscopy Lesion Scale (PULS). The stone-free rate (SFR) was defined as absolute and relative. Results: Baseline demographics, stone size, and stone location were comparable between groups. Dual-lumen use was associated with shorter operative time (38.6 ± 9.3 vs 52.7 ± 8.1 minutes, p = 0.018), shorter fluoroscopy time (23.6 ± 5.5 vs 34.2 ± 4.7 seconds, p = 0.04), and higher clarity-of-vision scores (8.6 ± 1.35 vs 5.9 ± 1.86, p = 0.035). UAS insertion failed more often with the dual-lumen scope (20.0% vs 10.0%, p = 0.32). One month after evaluation, SFR did not significantly differ between the two groups. Postoperative complications were infrequent (12.5% vs 10.0%, p = 0.72), all were Clavien–Dindo grade I–II, and no PULS grade ≥4 ureteral injuries occurred. Conclusions: Compared with a reusable single-lumen ureteroscope, the dual-lumen device improved operative efficiency in terms of shorter operative and fluoroscopy time and better clarity of vision. These benefits are counterbalanced by a higher UAS insertion failure rate related to the larger outer diameter of the ureteroscope.
- Top Cited PapersOpen Access
- 7 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1324
Clinical Implications of Paternal Age in Assisted Reproduction: Integrating Sperm Epigenetic Evidence
Background: Advanced paternal age is increasingly encountered in assisted reproduction as parenthood is deferred. The clinical question is whether paternal age from about 40 to 45 years and older affects embryo development or outcomes, and to what extent any effect relates to the sperm epigenome. Methods: This narrative review synthesized PubMed-indexed evidence on sperm aging biology, including DNA methylation, chromatin packaging and nucleosome retention, small non-coding RNAs, telomere dynamics, DNA fragmentation, and oxidative and mitochondrial stress, and their potential clinical impact on assisted reproduction outcomes. Results: Maternal age remains the principal determinant of embryo aneuploidy. After multivariable adjustment, independent paternal-age effects on fertilization, blastocyst formation, and preimplantation genetic testing for aneuploidy are small or not detected. At very advanced paternal ages near or above 50 years, some studies report higher miscarriage and lower live birth, without a consistent change in early embryo morphology. Aging in men is linked to higher DNA fragmentation and oxidative and mitochondrial signatures, together with reproducible sperm-epigenome changes, including age-linked DNA methylation, altered histone retention, and small-RNA shifts. These molecular findings support modest intergenerational influences on early development, while stable transgenerational inheritance in humans is not supported. Conclusions: Advanced paternal age should be regarded as a risk modifier rather than a primary driver of preimplantation failure. Counseling should emphasize realistic effect sizes and the predominance of maternal age. Laboratory workflows should minimize oxidative stress. Selective DNA-fragmentation testing may be appropriate in recurrent ART failure or recurrent loss. Sperm-epigenome assays remain investigational and should undergo prospective, standardized validation before use in routine care.
- 7 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1324
Top Cited PapersOpen AccessClinical Implications of Paternal Age in Assisted Reproduction: Integrating Sperm Epigenetic Evidence
Background: Advanced paternal age is increasingly encountered in assisted reproduction as parenthood is deferred. The clinical question is whether paternal age from about 40 to 45 years and older affects embryo development or outcomes, and to what extent any effect relates to the sperm epigenome. Methods: This narrative review synthesized PubMed-indexed evidence on sperm aging biology, including DNA methylation, chromatin packaging and nucleosome retention, small non-coding RNAs, telomere dynamics, DNA fragmentation, and oxidative and mitochondrial stress, and their potential clinical impact on assisted reproduction outcomes. Results: Maternal age remains the principal determinant of embryo aneuploidy. After multivariable adjustment, independent paternal-age effects on fertilization, blastocyst formation, and preimplantation genetic testing for aneuploidy are small or not detected. At very advanced paternal ages near or above 50 years, some studies report higher miscarriage and lower live birth, without a consistent change in early embryo morphology. Aging in men is linked to higher DNA fragmentation and oxidative and mitochondrial signatures, together with reproducible sperm-epigenome changes, including age-linked DNA methylation, altered histone retention, and small-RNA shifts. These molecular findings support modest intergenerational influences on early development, while stable transgenerational inheritance in humans is not supported. Conclusions: Advanced paternal age should be regarded as a risk modifier rather than a primary driver of preimplantation failure. Counseling should emphasize realistic effect sizes and the predominance of maternal age. Laboratory workflows should minimize oxidative stress. Selective DNA-fragmentation testing may be appropriate in recurrent ART failure or recurrent loss. Sperm-epigenome assays remain investigational and should undergo prospective, standardized validation before use in routine care.
- Open Access
- 27 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9) , 3022
Evaluating the Diagnostic Role of the Testosterone-to-Prostate-Specific Antigen Ratio in Pre-Biopsy Risk Stratification of Prostate Cancer
Background: The testosterone-to-PSA (T/PSA) ratio has been proposed as a novel biomarker to enhance the diagnostic specificity of prostate-specific antigen (PSA) in prostate cancer (PCa) detection. The objective of this study was to evaluate the diagnostic performance of the T/PSA ratio in distinguishing PCa from benign conditions in men undergoing prostate biopsy. Materials and Methods: Eighty men who underwent systematic and targeted transrectal prostate biopsy were retrospectively studied. Clinical variables included serum PSA, testosterone, prostate volume, PSA density (PSAD), and the T/PSA ratio. Diagnostic accuracy was assessed using Receiver Operating Characteristic (ROC) curve analysis. Optimal cutoffs were determined using Youden’s index. Results: PCa was diagnosed in 53 patients (66.3%). Median T/PSA was significantly lower in PCa versus non-PCa patients (0.46 vs. 0.86; p < 0.01). T/PSA showed good diagnostic performance (AUC = 0.75) with an optimal cutoff of 0.81 (sensitivity: 59.3%, specificity: 86.8%). In patients with PSA ≤10 ng/mL, T/PSA retained strong discriminatory ability (AUC = 0.76), with sensitivity and specificity of 82.4% and 72.7%, respectively. Among all parameters, PSAD showed the highest diagnostic accuracy (AUC = 0.813). T/PSA was not significantly associated with Gleason score (p = 0.48). Conclusions: The T/PSA ratio is a clinically accessible and cost-effective biomarker that may improve PCa risk stratification and reduce unnecessary biopsies, particularly in patients with borderline PSA levels. Although it does not correlate with tumor aggressiveness, its combination with PSAD could enhance diagnostic accuracy in routine clinical practice.
- 27 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9) , 3022
Open AccessEvaluating the Diagnostic Role of the Testosterone-to-Prostate-Specific Antigen Ratio in Pre-Biopsy Risk Stratification of Prostate Cancer
Background: The testosterone-to-PSA (T/PSA) ratio has been proposed as a novel biomarker to enhance the diagnostic specificity of prostate-specific antigen (PSA) in prostate cancer (PCa) detection. The objective of this study was to evaluate the diagnostic performance of the T/PSA ratio in distinguishing PCa from benign conditions in men undergoing prostate biopsy. Materials and Methods: Eighty men who underwent systematic and targeted transrectal prostate biopsy were retrospectively studied. Clinical variables included serum PSA, testosterone, prostate volume, PSA density (PSAD), and the T/PSA ratio. Diagnostic accuracy was assessed using Receiver Operating Characteristic (ROC) curve analysis. Optimal cutoffs were determined using Youden’s index. Results: PCa was diagnosed in 53 patients (66.3%). Median T/PSA was significantly lower in PCa versus non-PCa patients (0.46 vs. 0.86; p < 0.01). T/PSA showed good diagnostic performance (AUC = 0.75) with an optimal cutoff of 0.81 (sensitivity: 59.3%, specificity: 86.8%). In patients with PSA ≤10 ng/mL, T/PSA retained strong discriminatory ability (AUC = 0.76), with sensitivity and specificity of 82.4% and 72.7%, respectively. Among all parameters, PSAD showed the highest diagnostic accuracy (AUC = 0.813). T/PSA was not significantly associated with Gleason score (p = 0.48). Conclusions: The T/PSA ratio is a clinically accessible and cost-effective biomarker that may improve PCa risk stratification and reduce unnecessary biopsies, particularly in patients with borderline PSA levels. Although it does not correlate with tumor aggressiveness, its combination with PSAD could enhance diagnostic accuracy in routine clinical practice.
- Open Access
- 29 March 2025
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2025 (4) , rjaf235
Isolated pulmonary metastatic disease from prostate cancer as an initial symptom in a patient following transurethral resection of the prostate for benign disease with normal histopathology
Benign prostatic hyperplasia (BPH) remains a predominant cause of acute urinary retention (AUR) in elderly males. Transurethral resection of the prostate (TURP) is the gold-standard treatment for BPH, often uncovering incidental prostate cancer (IPC). Here, we present a unique case of an 80-year-old patient with refractory AUR due to BPH who underwent TURP. Despite benign histopathology, the patient developed isolated pulmonary metastases as the initial symptom of prostate cancer (PCa) eight months postoperatively. Diagnostic evaluation revealed advanced PCa with a Gleason Score of 8 and no other metastases. The rapid progression suggests potential vascular dissemination during TURP, although evidence remains inconclusive. This case highlights the importance of diligent follow-up post-TURP to exclude occult PCa, particularly in high-risk patients. The findings also raise questions about current histopathological evaluation protocols and the need for standardized follow-up practices to improve early detection and management of advanced PCa.
- 29 March 2025
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2025 (4) , rjaf235
Open AccessIsolated pulmonary metastatic disease from prostate cancer as an initial symptom in a patient following transurethral resection of the prostate for benign disease with normal histopathology
Benign prostatic hyperplasia (BPH) remains a predominant cause of acute urinary retention (AUR) in elderly males. Transurethral resection of the prostate (TURP) is the gold-standard treatment for BPH, often uncovering incidental prostate cancer (IPC). Here, we present a unique case of an 80-year-old patient with refractory AUR due to BPH who underwent TURP. Despite benign histopathology, the patient developed isolated pulmonary metastases as the initial symptom of prostate cancer (PCa) eight months postoperatively. Diagnostic evaluation revealed advanced PCa with a Gleason Score of 8 and no other metastases. The rapid progression suggests potential vascular dissemination during TURP, although evidence remains inconclusive. This case highlights the importance of diligent follow-up post-TURP to exclude occult PCa, particularly in high-risk patients. The findings also raise questions about current histopathological evaluation protocols and the need for standardized follow-up practices to improve early detection and management of advanced PCa.
- Open Access
- 27 March 2025
- Published by Springer Nature in BMC Urology
- Vol. 25 (1) , 1-8
Redo laparoscopic pyeloplasty for recurrent ureteropelvic junction obstruction: a single center experience and a review of the literature
To describe and analyze our experience with secondary (redo) laparoscopic pyeloplasty (rLP) in managing recurrent ureteropelvic junction obstruction (UPJO) following primary pyeloplasty, and to compare our outcomes with those reported in the existing literature. A retrospective analysis was conducted on patients who underwent rLP for recurrent UPJO. Baseline characteristics, detailed histories of previous pyeloplasties, operative profiles, and follow-up data were collected and analyzed. Furthermore, a comprehensive literature review was performed using PubMed. The study included eight patients (four men, four women) with a mean age of 27 years who underwent rLP. Among them, three had left-side and five had right-side involvement. Three patients had undergone open pyeloplasty, three laparoscopic pyeloplasty, one robot-assisted pyeloplasty, and one laparoscopic pyeloplasty and failed salvage endopyelotomy. Recurrent UPJO etiologies were recurrent stenosis (five cases), fibrosis and adhesions (two cases), and a combination of fibrosis, adhesions, and high insertion (one case). No crossing vessels were involved. Seven patients were treated using the dismembered technique, and one with Y-V plasty. The mean operation time was 185 min (range 150–240), and all procedures were completed laparoscopically. No blood transfusions were required intra- or postoperatively. The mean hospital stay was 2.8 days (range 2–4). Two patients (25%) experienced postoperative complications (one Clavien grade II and one Clavien grade IIIa). The mean follow-up period was 39 months (range 18–78), with a success rate of 87.5%. This study contributes additional evidence that rLP is an effective and reliable treatment for secondary UPJO, achieving high success rates despite its technical challenges.
- 27 March 2025
- Published by Springer Nature in BMC Urology
- Vol. 25 (1) , 1-8
Open AccessRedo laparoscopic pyeloplasty for recurrent ureteropelvic junction obstruction: a single center experience and a review of the literature
To describe and analyze our experience with secondary (redo) laparoscopic pyeloplasty (rLP) in managing recurrent ureteropelvic junction obstruction (UPJO) following primary pyeloplasty, and to compare our outcomes with those reported in the existing literature. A retrospective analysis was conducted on patients who underwent rLP for recurrent UPJO. Baseline characteristics, detailed histories of previous pyeloplasties, operative profiles, and follow-up data were collected and analyzed. Furthermore, a comprehensive literature review was performed using PubMed. The study included eight patients (four men, four women) with a mean age of 27 years who underwent rLP. Among them, three had left-side and five had right-side involvement. Three patients had undergone open pyeloplasty, three laparoscopic pyeloplasty, one robot-assisted pyeloplasty, and one laparoscopic pyeloplasty and failed salvage endopyelotomy. Recurrent UPJO etiologies were recurrent stenosis (five cases), fibrosis and adhesions (two cases), and a combination of fibrosis, adhesions, and high insertion (one case). No crossing vessels were involved. Seven patients were treated using the dismembered technique, and one with Y-V plasty. The mean operation time was 185 min (range 150–240), and all procedures were completed laparoscopically. No blood transfusions were required intra- or postoperatively. The mean hospital stay was 2.8 days (range 2–4). Two patients (25%) experienced postoperative complications (one Clavien grade II and one Clavien grade IIIa). The mean follow-up period was 39 months (range 18–78), with a success rate of 87.5%. This study contributes additional evidence that rLP is an effective and reliable treatment for secondary UPJO, achieving high success rates despite its technical challenges.
- Open Access
- 20 March 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-7
Unveiling the challenges of UTUC biopsies and cytology: insights from a global real-world practice study
Purpose: Diagnostic ureteroscopy (dURS) is optional in the assessment of patients with upper tract urothelial carcinoma (UTUC) and provides the possibility of obtaining histology. Methods: To evaluate endoscopic biopsy techniques and outcomes, we assessed data from patients from the CROES-UTUC registry. The registry includes multicenter prospective collected data on diagnosis and management of patients suspected having UTUC. Results: We assessed 2380 patients from 101 centers. dURS with biopsy was performed in 31.6% of patients. The quality of samples was sufficient for diagnosis in 83.5% of cases. There was no significant association between biopsy techniques and quality (p = 0.458). High-grade biopsy accurately predicted high-grade disease in 95.7% and high-risk stage disease in 86%. In ureteroscopic low-grade tumours, the prediction of subsequent low-grade disease was 66.9% and low-risk stage Ta-disease 35.8%. Ureteroscopic staging correctly predicted non-invasive Ta-disease and ≥ T1 disease in 48.9% and 47.9% of patients, respectively. Cytology outcomes did not provide additional value in predicting tumour grade. Conclusion: Biopsy results adequately predict high-grade and high-risk disease, but approximately one-third of patients are under-staged. Two-thirds of patients with low-grade URS-biopsy have high-risk stage disease, highlighting the need for improved diagnostics to better assess patient risk and guide treatment decisions. Clinical trial registration: The study was registered at ClinicalTrials.gov (ClinicalTrials.gov NCT02281188; https://clinicaltrials.gov/ct2/show/NCT02281188).
- 20 March 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-7
Open AccessUnveiling the challenges of UTUC biopsies and cytology: insights from a global real-world practice study
Purpose: Diagnostic ureteroscopy (dURS) is optional in the assessment of patients with upper tract urothelial carcinoma (UTUC) and provides the possibility of obtaining histology. Methods: To evaluate endoscopic biopsy techniques and outcomes, we assessed data from patients from the CROES-UTUC registry. The registry includes multicenter prospective collected data on diagnosis and management of patients suspected having UTUC. Results: We assessed 2380 patients from 101 centers. dURS with biopsy was performed in 31.6% of patients. The quality of samples was sufficient for diagnosis in 83.5% of cases. There was no significant association between biopsy techniques and quality (p = 0.458). High-grade biopsy accurately predicted high-grade disease in 95.7% and high-risk stage disease in 86%. In ureteroscopic low-grade tumours, the prediction of subsequent low-grade disease was 66.9% and low-risk stage Ta-disease 35.8%. Ureteroscopic staging correctly predicted non-invasive Ta-disease and ≥ T1 disease in 48.9% and 47.9% of patients, respectively. Cytology outcomes did not provide additional value in predicting tumour grade. Conclusion: Biopsy results adequately predict high-grade and high-risk disease, but approximately one-third of patients are under-staged. Two-thirds of patients with low-grade URS-biopsy have high-risk stage disease, highlighting the need for improved diagnostics to better assess patient risk and guide treatment decisions. Clinical trial registration: The study was registered at ClinicalTrials.gov (ClinicalTrials.gov NCT02281188; https://clinicaltrials.gov/ct2/show/NCT02281188).